| Type | Public (Euronext: GBT) |
|---|---|
| Founded | 1926 |
| Headquarters |  93420 Villepinte |
| Industry | Pharmaceutical |
| Revenue | € 0.3 billion (2006) |
| Employees | 1,250 (2006) |
| Website | www.guerbet.com |
Guerbet is a research-centered pharmaceutical company based in France that is one of the major players in the contrast agents business.
The company's main products are:
- Xenetix (Iobitridol) - X-ray contrast agent marketed mainly in Europe;
- Oxilan (Ioxilan) - X-ray contrast agent marketed mainly in the United States;
- Dotarem (Gadoteric acid) - MRI contrast agent marketed mainly in Europe.
History
The company is named after the french chemist Marcel Guerbet (1861-1938) , who produced Lipiodol in 1901 and his son Andre Guerbert, who founded the company in 1926. The X-ray contrast properties of Lipiodol were discovered in 1918.
|
|||||
 |
This article about a medical, pharmaceutical or biotechnological corporation or company is a stub. You can help Wikipedia by expanding it. |
This entry is from Wikipedia, the leading user-contributed encyclopedia. It may not have been reviewed by professional editors (see full disclaimer)
